Browse News
Filter News
Found 750,784 articles
-
BMS is terminating a seven-year-old gene therapy collaboration to develop potential treatments for congestive heart failure with uniQure N.V. valued at $1 billion.
-
As the FDA cracks down on accelerated approvals, Genentech, a Roche company, voluntarily withdrew its Tecentriq metastatic in bladder cancer.
-
AstraZeneca and Neogene have entered into a definitive acquisition agreement in which AstraZeneca will buy all outstanding equity in the smaller company.
-
With $96 million in Series A financing, Cajal Neuroscience launched Tuesday to develop drug candidates to target neurodegeneration in Alzheimer’s and Parkinson’s diseases.
-
BigHat Biosciences will team up with Merck to design candidates for three drug discovery programs backed by the company’s proprietary AI technology platform.
-
A second patient death has been linked to the Phase III clinical trial of Eisai and Biogen’s investigational Alzheimer's drug lecanemab, according to the journal Science.
-
The layoffs trend in the life sciences industry is continuing into the final months of 2022. See inside for details on which companies are reducing staff to increase cash flow.
-
Ghosting employers is the professional equivalent of standing up to someone for a date, and it can ruin your professional reputation, especially in the tight-knit biopharma industry.
-
Synexis® Appoints New Chief Executive Officer and Chief Commercial Officer
11/29/2022
Today, Synexis ® , LLC announced the appointment of Dennis Doyle as the new chief executive officer (CEO) and James "Jimmy" Robert as its first chief commercial officer (CCO).
-
Biocon Biologics Completes Acquisition of Viatris' Global Biosimilars Business
11/29/2022
Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), announced that it has successfully completed its multi-billion-dollar (USD) acquisition of the global biosimilars business of its partner Viatris Inc. (NASDAQ: VTRS).
-
Mission Bio's single-cell transduction assay adopted for AVROBIO's gene therapy pipeline
11/29/2022
Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the first-time deployment of one single-cell transduction assay across gene therapy company AVROBIO's lysosomal disorder pipeline.
-
Sinoveda Provides a Pain Relief Option That Is Only Possible When East Meets West
11/29/2022
The health and wellness industry is currently suffering from an excess of pain relief options.
-
Cambridge Cognition and Luca Healthcare Announce a Strategic Partnership and an Exclusive Licensing Agreement to Commercialize Cambridge Cognition's Suite of Cognitive Assessment Tools and Brain Health Products for the China Market
11/29/2022
Cambridge Cognition and Luca Healthcare announces a strategic partnership and a 10-year exclusive licensing agreement to commercialize Cambridge Cognition's suite of cognitive assessment tools in the China market.
-
Trinity Life Sciences Illuminates Optimal Competitive Intelligence Approaches With Qualitative Study
11/29/2022
Trinity Life Sciences , a leader in global life sciences commercialization solutions, sees competitive intelligence (CI) leaders in life sciences moving beyond data mining and monitoring to deliver accurate, robust insights.
-
Sonic Healthcare Acquires Strategic Stake in Microba Life Sciences, Establishes Significant Commercial Partnership
11/29/2022
Microba Life Sciences Limited is pleased to announce that leading medical diagnostics provider Sonic Healthcare Limited has agreed to invest $17.8m to acquire a 19.99% shareholding in Microba.
-
Autobahn Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ABX-002 for the Treatment for Major Depressive Disorder
11/29/2022
Autobahn Therapeutics today announced the initiation of dosing in the company’s Phase 1 clinical trial of ABX-002 in healthy volunteers.
-
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
11/29/2022
Full-Life Technologies, a fully integrated global radiotherapeutics company, announced an agreement to acquire New Jersey-based Focus-X Therapeutics, a company developing targeted radiopharmaceuticals to treat cancer based on proprietary peptide engineering technology.
-
Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals
11/29/2022
Zymeworks Inc. today announced that the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976, as amended, for the previously announced license agreement of zanidatamab, a HER2-targeted bispecific antibody, with Jazz Pharmaceuticals has expired.
-
Bryn Pharma Strengthens Board of Directors with Appointments of Commercial Veterans Sandy Loreaux and William D. Humphries
11/29/2022
Bryn Pharma LLC today announced the appointments of Sandy Loreaux and William D. Humphries to its Board of Directors.
-
Vergent Bioscience Awarded National Cancer Institute Phase 2 Grant to Advance Clinical Development of VGT-309 in Lung Cancer
11/29/2022
Vergent Bioscience Awarded National Cancer Institute Phase 2 Grant to Advance Clinical Development of VGT-309 in Lung Cancer.